OBJECTIVE: To compare the safety and efficacy of intravenous (IV) ciprofloxacin plus IV metronidazole (CIP+MET) with that of IV piperacillin/tazobactam (PIP/TAZO) in adults with complicated intraabdominal infections, and to compare the efficacy of sequential IV-to-oral CIP+MET therapy with that of the IV CIP-only regimen. SUMMARY BACKGROUND DATA: Treatment of intraabdominal infections remains a challenge, mainly because of their polymicrobial etiology and attendant death and complications. Antimicrobial regimens using sequential IV-to-oral therapy may reduce the length of hospital stay. METHODS: In this multicenter, randomized, double-blind trial involving 459 patients, clinically improved IV-treated patients were switched to oral therapy after 48 hours. Overall clinical response was the primary efficacy measurement. RESULTS: A total of 282 patients (151 CIP+MET, 131 PIP/TAZO) were valid for efficacy. Of these patients, 64% CIP+MET and 57% PIP/TAZO patients were considered candidates for oral therapy. Patients had a mean APACHE II score of 9.6. The most common diagnoses were appendicitis (33%), other intraabdominal infection (29%), and abscess (25%). Overall clinical resolution rates were statistically superior for CIP+MET (74%) compared with PIP/TAZO (63%). Corresponding rates in the subgroup suitable for oral therapy were 85% for CIP+MET and 70% for PIP/TAZO. Postsurgical wound infection rates were significantly lower in CIP+MET (11%) versus PIP/TAZO patients (19%). Mean length of stay was 14 days for CIP+MET and 17 days for PIP/TAZO patients. CONCLUSION:CIP+MET, initially administered IV and followed by CIP+MET oral therapy, was clinically more effective than IV PIP/TAZO for the treatment of patients with complicated intraabdominal infections.
RCT Entities:
OBJECTIVE: To compare the safety and efficacy of intravenous (IV) ciprofloxacin plus IV metronidazole (CIP+MET) with that of IV piperacillin/tazobactam (PIP/TAZO) in adults with complicated intraabdominal infections, and to compare the efficacy of sequential IV-to-oral CIP+MET therapy with that of the IV CIP-only regimen. SUMMARY BACKGROUND DATA: Treatment of intraabdominal infections remains a challenge, mainly because of their polymicrobial etiology and attendant death and complications. Antimicrobial regimens using sequential IV-to-oral therapy may reduce the length of hospital stay. METHODS: In this multicenter, randomized, double-blind trial involving 459 patients, clinically improved IV-treated patients were switched to oral therapy after 48 hours. Overall clinical response was the primary efficacy measurement. RESULTS: A total of 282 patients (151 CIP+MET, 131 PIP/TAZO) were valid for efficacy. Of these patients, 64% CIP+MET and 57% PIP/TAZO patients were considered candidates for oral therapy. Patients had a mean APACHE II score of 9.6. The most common diagnoses were appendicitis (33%), other intraabdominal infection (29%), and abscess (25%). Overall clinical resolution rates were statistically superior for CIP+MET (74%) compared with PIP/TAZO (63%). Corresponding rates in the subgroup suitable for oral therapy were 85% for CIP+MET and 70% for PIP/TAZO. Postsurgical wound infection rates were significantly lower in CIP+MET (11%) versus PIP/TAZO patients (19%). Mean length of stay was 14 days for CIP+MET and 17 days for PIP/TAZO patients. CONCLUSION:CIP+MET, initially administered IV and followed by CIP+MET oral therapy, was clinically more effective than IV PIP/TAZO for the treatment of patients with complicated intraabdominal infections.
Authors: B Brismar; A S Malmborg; G Tunevall; B Wretlind; L Bergman; L O Mentzing; P O Nyström; E Kihlström; B Bäckstrand; T Skau Journal: Antimicrob Agents Chemother Date: 1992-12 Impact factor: 5.191
Authors: H C Polk; M P Fink; M Laverdiere; S E Wilson; G E Garber; P S Barie; J C Hebert; W G Cheadle Journal: Am Surg Date: 1993-09 Impact factor: 0.688
Authors: J Niinikoski; T Havia; E Alhava; M Pääkkönen; P Miettinen; E Kivilaakso; R Haapiainen; M Matikainen; S Laitinen Journal: Surg Gynecol Obstet Date: 1993-03
Authors: Gabrio Bassotti; Fabio Chistolini; Francis Sietchiping-Nzepa; Giuseppe De-Roberto; Antonio Morelli Journal: World J Gastroenterol Date: 2004-08-01 Impact factor: 5.742
Authors: P Seguin; C Brianchon; Y Launey; B Laviolle; N Nesseler; P-Y Donnio; Y Malledant Journal: Eur J Clin Microbiol Infect Dis Date: 2011-11-12 Impact factor: 3.267
Authors: Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel Journal: Can J Infect Dis Med Microbiol Date: 2010 Impact factor: 2.471
Authors: Puja M Shah; Brandy L Edwards; Zachary C Dietch; Christopher A Guidry; Stephen W Davies; Sara A Hennessy; Therese M Duane; Patrick J O'Neill; Raul Coimbra; Charles H Cook; Reza Askari; Kimberly Popovsky; Robert G Sawyer Journal: Surg Infect (Larchmt) Date: 2015-09-23 Impact factor: 2.150
Authors: Teena Chopra; Jing J Zhao; George Alangaden; Michael H Wood; Keith S Kaye Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2010-06 Impact factor: 2.217
Authors: Ina Willemsen; Ben Cooper; Carin van Buitenen; Marjolein Winters; Gunnar Andriesse; Jan Kluytmans Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191